A share price of Myriad Genetics, Inc [MYGN] is currently trading at $4.19, up 0.72%. An important factor to consider is whether the stock is rising or falling in short-term value. The MYGN shares have gain 6.62% over the last week, with a monthly amount drifted -43.45%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Myriad Genetics, Inc [NASDAQ: MYGN] stock has seen the most recent analyst activity on May 21, 2025, when Scotiabank downgraded its rating to a Sector Perform but kept the price target unchanged to $6 for it. Previously, Wolfe Research downgraded its rating to Peer Perform on May 08, 2025. On May 07, 2025, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $6 on the stock. Guggenheim downgraded its rating to a Neutral. Piper Sandler upgraded its rating to a Overweight and raised its price target to $12.50 on March 12, 2025. Craig Hallum started tracking with a Buy rating for this stock on February 12, 2025, and assigned it a price target of $29. In a note dated December 10, 2024, UBS initiated an Neutral rating and provided a target price of $18 on this stock.
Myriad Genetics, Inc experienced fluctuations in its stock price throughout the past year between $3.81 and $29.30. Currently, Wall Street analysts expect the stock to reach $12.9 within the next 12 months. Myriad Genetics, Inc [NASDAQ: MYGN] shares were valued at $4.19 at the most recent close of the market. An investor can expect a potential return of 207.88% based on the average MYGN price forecast.
Analyzing the MYGN fundamentals
Trailing Twelve Months sales for Myriad Genetics, Inc [NASDAQ:MYGN] were 831.30M which represents -3.12% decline. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.15 and Total Capital is -0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.04 points at the first support level, and at 3.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.29, and for the 2nd resistance point, it is at 4.39.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Myriad Genetics, Inc [NASDAQ:MYGN] is 1.90. On the other hand, the Quick Ratio is 1.71, and the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 0.46, the price to book ratio is 0.55.
Transactions by insiders
Recent insider trading involved DIAZ PAUL J, President and CEO, that happened on Oct 11 ’24 when 15000.0 shares were sold. Officer, DIAZ PAUL J completed a deal on Oct 11 ’24 to buy 15000.0 shares. Meanwhile, Officer Ancona Margaret bought 11538.0 shares on Aug 21 ’24.
